← Back to Clinical Trials
Recruiting NCT05407168

NCT05407168 Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05407168
Status Recruiting
Phase
Sponsor OHSU Knight Cancer Institute
Condition Lung Carcinoma
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2022-10-31
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
Best PracticeHealth Promotion and EducationQuestionnaire Administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2022-10-31 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial evaluates the effectiveness of a conversation tool on patient-centered health and decision-making outcomes in patients with lung cancer making treatment decisions. This research is being conducted to help doctors understand the information patients need to participate in shared decision-making about their lung cancer treatment options. The focus of this research is to study how patients choose lung cancer treatment options and the information needed to make that choice, with a focus on patients with lower health literacy.

Eligibility Criteria

Inclusion Criteria: * AIM 1: Suspected lung cancer * AIM 1: English fluency * AIM 1: \> 6-month life expectancy * AIM 1: Score of ≥ 3 on the cognitive impairment screener * AIM 2 PARTICIPANTS: Participation in Aim 1 * AIM 2 CLINICIANS: Discussing lung cancer treatment decisions with Aim 1 participants

Contact & Investigator

Principal Investigator

Donald R Sullivan, MD, MA, MCR

PRINCIPAL INVESTIGATOR

OHSU Knight Cancer Institute

Frequently Asked Questions

Who can join the NCT05407168 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05407168 currently recruiting?

Yes, NCT05407168 is actively recruiting participants. Visit ClinicalTrials.gov or contact OHSU Knight Cancer Institute to inquire about joining.

Where is the NCT05407168 trial being conducted?

This trial is being conducted at Hillsboro, United States, Portland, United States, Portland, United States, Portland, United States.

Who is sponsoring the NCT05407168 clinical trial?

NCT05407168 is sponsored by OHSU Knight Cancer Institute. The principal investigator is Donald R Sullivan, MD, MA, MCR at OHSU Knight Cancer Institute. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology